<bill session="115" type="h" number="6478" updated="2023-01-11T13:41:58Z">
  <state datetime="2018-07-23">REFERRED</state>
  <status>
    <introduced datetime="2018-07-23"/>
  </status>
  <introduced datetime="2018-07-23"/>
  <titles>
    <title type="display">Biosimilars Competition Act of 2018</title>
    <title type="official" as="introduced">To enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding biologic and biosimilar products, and for other purposes.</title>
    <title type="short" as="introduced">Biosimilars Competition Act of 2018</title>
  </titles>
  <sponsor bioguide_id="S001168"/>
  <cosponsors>
    <cosponsor bioguide_id="J000292" joined="2018-07-23"/>
  </cosponsors>
  <actions>
    <action datetime="2018-07-23">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-07-23" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2018-07-27">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Contracts and agency"/>
    <term name="Department of Justice"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-20T19:49:43Z" status="Introduced in House">Biosimilars Competition Act of 2018

This bill amends the Public Health Service Act to require a biologic manufacturer and a biosimilar drug manufacturer to provide notification to the Department of Justice and the Federal Trade Commission regarding certain pharmaceutical agreements. The agreements requiring notice are those related to the manufacturer, marketing or sale of the biosimilar product or the reference product.

Biosimilars are biological products approved by the Food and Drug Administration based on their similarity to an already-approved biological product.</summary>
</bill>
